|
- 积分
- 85
- 威望
- 85
- 包包
- 41
|
1Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study
% l+ ]( {5 r1 _ `http://circheartfailure.ahajournals.org/content/6/4/711.long
8 V1 K7 V1 O8 ]( r6 K2，Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy: Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) http://circheartfailure.ahajournals.org/content/7/1/51.long
[6 I8 |' N3 e% N9 ?) M, Y& V3，Incidence, Predictors and Outcomes Related to Hypo and Hyperkalemia in Severe Heart Failure Patients Treated with a Mineralocorticoid Receptor Antagonist.
+ z6 G6 p3 l. J! |# k& D' }' t$ whttp://www-ncbi-nlm-nih-gov.ezpr ... Receptor+Antagonist
5 K2 u2 h7 F" V3 P |
|
发表于 2014-5-28 23:30
发表于 2014-5-29 09:32
